Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcitonin.

S L Silverman1

  • 1Department of Medicine, University of California Los Angeles, USA. stuarts@OMCresearch.org

Rheumatic Diseases Clinics of North America
|April 5, 2001
PubMed
Summary
This summary is machine-generated.

Calcitonin effectively lowers vertebral fracture risk in postmenopausal women with osteoporosis. While it increases spinal bone mass and reduces bone turnover, it does not significantly impact nonvertebral fractures but may offer pain relief.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Study of the Disputed Point in Local Anesthesia.

The Dental register·2021
Same author

Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same author

Bisphosphonate drug holidays: we reap what we sow.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Geriatric Medicine

Background:

  • Osteoporosis is a significant health concern in postmenopausal women, characterized by low bone mass and increased fracture risk.
  • Vertebral fractures are a common and debilitating complication of osteoporosis, leading to pain, disability, and reduced quality of life.

Purpose of the Study:

  • To evaluate the efficacy of calcitonin in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis.
  • To assess the effects of calcitonin on bone mineral density, bone turnover markers, and nonvertebral fracture incidence.
  • To explore the potential analgesic benefits of calcitonin in this patient population.

Main Methods:

  • A randomized controlled trial design was employed.
  • Participants received calcitonin or a placebo over a specified duration.

Related Experiment Videos

  • Bone mineral density, bone turnover markers, and fracture incidence were monitored throughout the study.

    • Main Results:

    • Calcitonin significantly reduced the risk of vertebral fractures compared to placebo.
    • Small but significant increases in spinal bone mass were observed in the calcitonin group.
    • Bone turnover markers showed a modest reduction with calcitonin treatment.
    • No significant difference in nonvertebral fracture rates was found between groups.
    • Calcitonin treatment was associated with a potential analgesic benefit.

    Conclusions:

    • Calcitonin is an effective treatment for reducing vertebral fracture risk in postmenopausal women with osteoporosis.
    • The therapeutic effect of calcitonin is primarily related to its impact on spinal bone mass and turnover.
    • Calcitonin may provide an additional benefit of pain relief for patients with osteoporosis.